Page 175 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild to moderately severe
donepezil 3mg placebo donepezil 5 mg 70.6 72.9 71.0 52.5 62.5 55 100% 94.9% 92.5% 0% 2.6% 7.5% 0% 2.6% 0% NR NR NR ome Measures: ADAS-Cog; CGIC Secondary Outcome Measures: ADL; MMSE; CDR-SB; QOL-P (patient); QOL-C (caregiver) Timing of assessments: Screening visit, baseline, and weeks 1, 3, 6, 9, 12 and 14 No significant differences between DON and placebo in quality of life (patient and caregiver) and DON 3 mg/d and 5 mg/d treated patients showed statistically significantly better ADAS-Cog scores than placebo-treated patients at e
Groups similar at baseline: Yes

donepezil 1mg 72.6 72.5 97.6% 2.4% 0% NR Primary Outc Health Outcome Measures: • activities of daily living measures Intermediate Outcome Measures: • • •

e population qualities:

Final Report Update 1 Authors: Rogers et al. Year: 1996 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other german OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs